Answers are grounded in this paper and cite their sources.
Case report demonstrates successful arteriovenous malformation treatment with trametinib in CM-AVM syndrome, highlighting MEK inhibition for managing cardiac compromise.
Capillary malformation-arteriovenous malformation (CM-AVM) syndrome is an autosomal dominant condition characterized by multifocal, noncontiguous pink patches on the skin that often have a surrounding pale halo. In some cases, an association with a fast flow, arteriovenous malformation (AVM) can be identified. Here, we describe a case report of a 16-year-old woman with CM-AVM syndrome and significant cardiac compromise successfully treated with trametinib, a mitogen-activated protein kinase (MEK) inhibitor.
No takes yet. Share an insight, caveat, or question.
Nicholson et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: